NCT04294641 2026-01-23
Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
Clinical Trials
10 trialsNCT02014558 2024-12-03
Dose Escalation Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Astellas Pharma Inc
Phase 1/2 Completed
NCT04551963 2024-10-26
Interaction Study of Zanubrutinib With Moderate and Strong CYP3A Inhibitors in Participants With B-Cell Malignancies
BeiGene
Phase 1 Completed
NCT01503515 2024-10-16
Caspofungin Acetate, Fluconazole, or Voriconazole in Preventing Fungal Infections in Patients Following Donor Stem Cell Transplant
Children's Oncology Group
Phase 3 Completed
NCT00075803 2023-01-04
BMT CTN 0101
Medical College of Wisconsin
Phase 3 Completed
NCT01416025 2016-08-18
VoriTDM
Johns Hopkins University
Phase 4 Completed
NCT01480219 2013-03-11
Evaluation Of The Importance Of Risk-Factor Adjustment For Assessing The Relationship Between Voriconazole Utilization And The Development Of Non-Melanoma Skin Cancer Among Lung And Heart/Lung Transplant Patients, 2002-2009g
Pfizer
Completed
NCT00418951 2012-08-07
Liposomal Amphotericin B (Ambisome) Versus Oral Voriconazole for the Prevention of Invasive Fungal Infections
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00904995 2012-08-07
Beta Glucan Assay in Patients Receiving Voriconazole Prophylaxis
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00143312 2009-10-06
VOSIFI
Pfizer
Phase 4 Completed